Navigation Links
InterMune To Release First Quarter Financial Results On April 24
Date:4/17/2013

BRISBANE, Calif., April 17, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its first quarter 2013 financial results at the close of the U.S. markets on Wednesday, April 24, 2013.  A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

(Logo: http://photos.prnewswire.com/prnh/20120827/SF62570LOGO)

Interested investors and others may participate in the conference call by dialing 800-891-8257 (U.S.) or +1 212-271-4651 (international), conference ID#21655193.  A replay of the webcast and teleconference will be available on the company's website approximately three hours after the call.  To access the live webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A telephonic replay will be available for 10 business days following the call and can be accessed by dialing 800-633-8284 (U.S.) or +1 402-977-9140 (international), and entering the conference ID#21655193. 

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.  In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved  for IPF anywhere in the world, is approved for marketing by InterMune in the EU and Canada as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
2. InterMune to Present at J. P. Morgan Healthcare Conference
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
4. InterMune To Present At JMP Securities Healthcare Conference
5. InterMune To Release Third Quarter Financial Results On November 7
6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
7. InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
8. ICD-10 Coding Knowledge Assessment Tool Released
9. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
10. Verify Brand™ Announces the Release of VB Enterprise 4.0
11. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Island, NY (PRWEB) , ... February 24, 2017 , ... ... rate. Founded in late 2014, FireflySci had the goal of bringing their powerful ... that goal continues to shape the path that FireflySci is going on as they ...
(Date:2/23/2017)... NEW YORK , Feb. 23, 2017 /PRNewswire/ ... leading digital health company, and Digital Noema ... and remote patient monitoring, announce they are partnering ... DN Telehealth maximizes collaboration compatibility for ... consultations beyond a physical clinical setting to include ...
(Date:2/23/2017)... 2017  MIODx announced today that it has ... technologies from the University of California, San Francisco ... monitor a patient for response to immune checkpoint ... second license extends the technology with a method ... have an immune-related adverse event (IRAE) from their ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... novo clearance to begin marketing the SPEAC® System, the Brain Sentinel® Seizure Monitoring ... home or in healthcare facilities during periods of rest. A lightweight, non-invasive monitor ...
Breaking Biology Technology:
(Date:2/7/2017)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that the latest release ... flexible and award winning eClinical solution, is now available ... is a proven Software-as-a-Service (SaaS) clinical research technology platform ... also delivers an entire suite of eClinical tools to ...
(Date:2/7/2017)... LONG BEACH, New York , February 7, 2017 ... formerly known as ID Global Solutions Corporation [OTC: IDGS], ... identification, identity management and electronic transaction processing services, is ... a reorganization of the Company. Effective January ... Chairman of the Board of Directors, CEO and President. ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute ... Larry Schlesinger as the Institute,s new President ... Biomed effective May 31, 2017. He is currently the Chair ... of the Center for Microbial Interface Biology at Ohio State ... as the new President and CEO of Texas Biomed," said ...
Breaking Biology News(10 mins):